Search
halofuginone; 7-bromo-6-chloro-3-[3-[(3R)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one; stenorol; tempostatin
extracted from plants
Indications:
- unclear if any clinical indications; some experimental success
- successfully used in some animal models of fibrotic diseases, & in a human scleroderma trial [2]
- protected mice from experimental autoimmune encephalomyelitis mediated by TH17 cells
Mechanism of action:
- inhibits differentiation of T-helper cells (TH17 cells), thus normalizing the TH17 to T-regulatory cell ratio
- appears to affect T-helper cells (TH17 cells) selectively
- activates amino acid starvation response
General
heterocyclic compound, 2 rings
ketone
pharmaceutical angiogenesis inhibitor (angiostatic agent)
phenol
pyridine
Database Correlations
PUBCHEM correlations
References
- Sundrud MS et al.
Halofuginone inhibits TH17 cell differentiation by activating
the amino acid starvation response.
Science 2009 Jun 5; 324:1334.
PMID: 19498172
http://dx.doi.org/10.1126/science.1172638
- Pines M et al
Halofuginone to treat fibrosis in chronic graft-versus-host
disease and scleroderma.
Biol Blood Marrow Transplant. 2003 Jul;9(7):417-25.
PMID: 12869955